Receiving a diagnosis of Chronic Myeloid Leukemia (CML) can be frightening, but it is important to understand that the management of this disease is one of the greatest success stories in modern ...
Trained immunity provides a unifying framework linking innate immune memory to both protective and maladaptive inflammation ...
Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market ...
Good day, and thank you for standing by. Welcome to the Terns Pharmaceuticals TERN-701 December 2025 Data Update Conference Call. Please be advised that today's conference is being recorded. I would ...
Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease experiencing chronic anemia reported improved quality of life after adding ...
The MarketWatch News Department was not involved in the creation of this content. -- Scemblix(R) is first to show superior efficacy and a favourable safety and tolerability profile in a Phase III ...
The 24-month EFS was 97% per protocol definition and 79% per post-hoc analysis, with the OS being 100%. Bosutinib shows promising efficacy in the treatment of children with newly diagnosed (ND) and ...
Chronic myeloid leukemia (CML) is a hematopoietic malignancy characterized by BCR-ABL1 gene fusion. The immune microenvironment, implicated in relapse and drug resistance, poses significant challenges ...
Department of Pediatrics, Blood and Marrow Transplantation and Cellular Therapy, King Hussein Cancer Center, Amman, Jordan Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized ...
Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...